n/a
Abstract Title:

Ellagic acid inhibits HIV-1 infection in vitro: Potential role as a novel microbicide.

Abstract Source:

Oral Dis. 2018 Mar ;24(1-2):249-252. PMID: 29480632

Abstract Author(s):

A Promsong, T Chuenchitra, K Saipin, S Tewtrakul, P Panichayupakaranant, S Satthakarn, W Nittayananta

Article Affiliation:

A Promsong

Abstract:

OBJECTIVE: To investigate the in vitro effects of ellagic acid on HIV-1 replication.

METHODS: Anti-HIV-1 activity of ellagic acid was determined in vitro using X4-tropic HIV-1and R5-tropic pBaL Env-recombinant virus. Anti-HIV-1activity of ellagic acid was investigated at a multiplicity of infection (MOI) of 0.01. Anti-HIV-1 integrase and protease activities of ellagic acid were tested using in vitro integration and proteolytic cleavage assays.

RESULTS: Ellagic acid, added either before or after HIV-1exposure, suppressed replication of the virus in C8166 cells up to 34%. Ellagic acid showed an anti-integrase ICof 8.7 μM. No cytotoxicity of ellagic acid at concentrations ranging from 12.5 to 100 μM was observed.

CONCLUSION: We conclude that ellagic acid can inhibit HIV-1 infection without cytotoxicity. Thus, it may be a new effective agent that has potential to be developed as a novel microbicide against HIV-1.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.